Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...
Bevacizumab (Avastin, Roche/Genentech) significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery ...
Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial ...
BERLIN — The combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, leads to significant improvements in survival outcomes in patients with platinum-resistant recurrent ...
Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic colorectal cancer. CRC is among the most common cancers worldwide while ...
What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).
MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumors: Still a need for liver biopsy? Development and validation of the SPEAR scoring model and predicting overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results